"The current publication which follows our announcement from 07 September 2011, further supports Pluristem's finding that the combination of the Placenta as a rich cell source and our propriety 3D manufacturing platform may lead to new product and therapies for unmet needs and will increase the level of awareness for our technology in the medical community," stated Pluristem Chairman and CEO Zami Aberman.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.
Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit
, the content of which is not part of this press release.
The Pluristem Therapeutics Inc. logo is available at
About Hadassah University Medical Center
Hadassah is a state-of-the-art medical center incorporating all medical and surgical sub-specialties, with a tertiary care referral hospital at Ein Kerem and a community hospital on Mt. Scopus; Hadassah Hospitals have 850 physicians and Academic University Affiliated researchers, 1,940 nurses, 1,020 paramedical and support staff,1,200 support stuff, 1,200 beds, 31 operating theaters, 9 intensive care units and over 120 outpatient clinics treating over 1 million people a year from all over Israel and from neighboring countries. Hadassah's Hospitals conduct more than half the medical research in Israel. The flagship of Hadassah, the Women's Zionist Organization of America, is the main supporter of the Hadassah Medical Center.